Tobias Boch

2.7k total citations · 1 hit paper
40 papers, 1.4k citations indexed

About

Tobias Boch is a scholar working on Epidemiology, Infectious Diseases and Hematology. According to data from OpenAlex, Tobias Boch has authored 40 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 13 papers in Infectious Diseases and 10 papers in Hematology. Recurrent topics in Tobias Boch's work include Antifungal resistance and susceptibility (13 papers), Fungal Infections and Studies (12 papers) and Acute Myeloid Leukemia Research (6 papers). Tobias Boch is often cited by papers focused on Antifungal resistance and susceptibility (13 papers), Fungal Infections and Studies (12 papers) and Acute Myeloid Leukemia Research (6 papers). Tobias Boch collaborates with scholars based in Germany, United States and Austria. Tobias Boch's co-authors include Andreas Trumpp, Dieter Buchheidt, Daniel Nowak, Thomas Michaeli, Simon Raffel, Christoph Lutz, Simon Haas, Daniel Tobias Michaeli, Lars M. Steinmetz and Lars Velten and has published in prestigious journals such as Nature Communications, Blood and Nature Cell Biology.

In The Last Decade

Tobias Boch

38 papers receiving 1.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human haematopoietic stem cell lineage commitment is a continuous process

2017 539 citations Lars Velten, Simon Haas et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tobias Boch Germany	18	482	388	387	313	307	40	1.4k
Carlos Richard Spain	24	730 1.5×	307 0.8×	479 1.2×	762 2.4×	390 1.3×	70	2.2k
Xueyan Xi China	16	418 0.9×	137 0.4×	196 0.5×	110 0.4×	492 1.6×	49	1.2k
Nadine Weich United States	15	806 1.7×	216 0.6×	396 1.0×	258 0.8×	334 1.1×	23	1.7k
Danielle M. Carrick United States	23	467 1.0×	76 0.2×	426 1.1×	227 0.7×	248 0.8×	35	1.6k
Utz Krug Germany	25	1.1k 2.3×	120 0.3×	136 0.4×	980 3.1×	233 0.8×	82	2.0k
Yung‐Li Yang Taiwan	19	358 0.7×	102 0.3×	120 0.3×	364 1.2×	78 0.3×	84	1.2k
James J. O’Leary United States	19	579 1.2×	103 0.3×	118 0.3×	149 0.5×	273 0.9×	67	1.4k
Shruti Sharma United States	14	411 0.9×	163 0.4×	81 0.2×	121 0.4×	654 2.1×	20	1.1k
Philippa L. Roddam United Kingdom	14	613 1.3×	81 0.2×	231 0.6×	223 0.7×	212 0.7×	19	1.1k
Ulrich Mack Germany	16	251 0.5×	169 0.4×	254 0.7×	230 0.7×	127 0.4×	26	860

Countries citing papers authored by Tobias Boch

Since Specialization

Citations

This map shows the geographic impact of Tobias Boch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tobias Boch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tobias Boch more than expected).

Fields of papers citing papers by Tobias Boch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tobias Boch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tobias Boch. The network helps show where Tobias Boch may publish in the future.

Co-authorship network of co-authors of Tobias Boch

This figure shows the co-authorship network connecting the top 25 collaborators of Tobias Boch. A scholar is included among the top collaborators of Tobias Boch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tobias Boch. Tobias Boch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Diehl, Steffen J., Tobias Boch, Frank G. Zöllner, et al.. (2025). Targeting tumoral heterogeneity in lung cancer: a novel, CT-texture-guided targeted biopsy approach with exome sequencing. npj Precision Oncology. 9(1). 342–342.

Michaeli, Daniel Tobias, Julia Caroline Michaeli, Sebastian Albers, Tobias Boch, & Thomas Michaeli. (2023). Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. American Journal of Cardiovascular Drugs. 23(5). 477–495. 52 indexed citations

Michaeli, Daniel Tobias, Thomas Michaeli, Sebastian Albers, Tobias Boch, & Julia Caroline Michaeli. (2023). Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. The European Journal of Health Economics. 25(6). 979–997. 53 indexed citations

Michaeli, Daniel Tobias, Julia Caroline Michaeli, Tobias Boch, & Thomas Michaeli. (2022). Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany. Cardiovascular Drugs and Therapy. 37(4). 683–694. 16 indexed citations

Michaeli, Julia Caroline, Daniel Tobias Michaeli, Tobias Boch, Sebastian Albers, & Thomas Michaeli. (2022). Socio‐economic burden of disease: Survivorship costs for renal cell carcinoma. European Journal of Cancer Care. 31(3). e13569–e13569. 2 indexed citations

Michaeli, Daniel Tobias, Julia Caroline Michaeli, Tobias Boch, & Thomas Michaeli. (2022). Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. Clinical Drug Investigation. 42(8). 643–656. 13 indexed citations

Boch, Tobias, Jens Köhler, Melanie Janning, & Sonja Loges. (2022). Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives. Cancer Biology and Medicine. 19(11). 1543–1564. 21 indexed citations

Velten, Lars, Pablo Hernández-Malmierca, Simon Raffel, et al.. (2021). Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. Nature Communications. 12(1). 1366–1366. 89 indexed citations

Boch, Tobias, Nikolaj Frost, Tobias R. Overbeck, et al.. (2021). Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery. Lung Cancer. 164. 46–51. 8 indexed citations

10.

Jenks, Jeffrey D., Juergen Prattes, Johanna Frank, et al.. (2020). Performance of the Bronchoalveolar Lavage FluidAspergillusGalactomannan Lateral Flow Assay With Cube Reader for Diagnosis of Invasive Pulmonary Aspergillosis: A Multicenter Cohort Study. Clinical Infectious Diseases. 73(7). e1737–e1744. 55 indexed citations

11.

Boch, Tobias, Birgit Spieß, Werner Heinz, et al.. (2019). Aspergillus specific nested PCR from the site of infection is superior to testing concurrent blood samples in immunocompromised patients with suspected invasive aspergillosis. Mycoses. 62(11). 1035–1042. 10 indexed citations

12.

Heldt, Sven, Juergen Prattes, Susanne Eigl, et al.. (2018). Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. Journal of Infection. 77(3). 235–241. 77 indexed citations

13.

Boch, Tobias, Mark Reinwald, Birgit Spieß, et al.. (2018). Detection of invasive pulmonary aspergillosis in critically ill patients by combined use of conventional culture, galactomannan, 1-3-beta-D-glucan and Aspergillus specific nested polymerase chain reaction in a prospective pilot study. Journal of Critical Care. 47. 198–203. 45 indexed citations

14.

Boch, Tobias, Oliver A. Cornely, Axel Hamprecht, et al.. (2018). Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients. Frontiers in Microbiology. 9. 555–555. 22 indexed citations

15.

Buchheidt, Dieter, Mark Reinwald, Wolf‐Karsten Hofmann, Tobias Boch, & Birgit Spieß. (2017). Evaluating the use of PCR for diagnosing invasive aspergillosis. Expert Review of Molecular Diagnostics. 17(6). 603–610. 13 indexed citations

16.

Buchheidt, Dieter, Mark Reinwald, Martin Hoenigl, et al.. (2017). The evolving landscape of new diagnostic tests for invasive aspergillosis in hematology patients: strengths and weaknesses. Current Opinion in Infectious Diseases. 30(6). 539–544. 15 indexed citations

17.

Eigl, Susanne, Martin Hoenigl, Birgit Spieß, et al.. (2016). Galactomannan testing andAspergillusPCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. Medical Mycology. 55(5). myw102–myw102. 74 indexed citations

18.

Boch, Tobias, Mark Reinwald, Oliver A. Cornely, et al.. (2015). Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA‐microarray from primary clinical samples. Mycoses. 58(12). 735–745. 28 indexed citations

19.

Boch, Tobias, Birgit Spieß, Oliver A. Cornely, et al.. (2015). Aspergillus Specific PCR and Galactomannan of Bronchoalveolar Lavage Are Superior to Concomitant Same-Day Testing of Concurrent Blood Samples in Immunocompromised Hematological Patients with Suspected Invasive Aspergillosis. Blood. 126(23). 2072–2072. 1 indexed citations

20.

Ehninger, Armin, Tobias Boch, Hannah J. Uckelmann, et al.. (2014). Posttranscriptional regulation of c-Myc expression in adult murine HSCs during homeostasis and interferon-α-induced stress response. Blood. 123(25). 3909–3913. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact